Skip to main content

Table 5 Multivariate logistic regression of risk factors according to specific major cardiovascular event

From: Metabolic syndrome in haemodialysis patients: prevalence, determinants and association to cardiovascular outcomes

 

CHD

PAD III-IV

STROKE

CHF

 

OR

p

95% CI

OR

p

95% CI

OR

p

95% CI

OR

p

95% CI

MetS

1.92

<  0.01

1.22–3.01

0.79

0.58

0.33–1.81

0.90

0.71

0.51–1.60

2.35

<  0.01

1.40–3.99

LDL (g/L)

1.09

0.07

0.99–1.20

0.82

0.06

0.66–1.01

0.95

0.43

0.84–1.08

1.09

0.10

0.98–1.21

Diabetes

1.76

<  0.01

1.18–2.63

5.90

<  0.01

2.78–12.5

1.89

0.01

1.14–3.14

1.32

0.26

0.81–2.15

Smoking

1.55

0.04

1.01–2.37

1.84

0.11

0.87–3.90

1.76

0.03

1.07–2.90

1.38

0.20

0.84–2.28

Age (year)

1.03

<  0.01

1.02–1.05

1.02

0.17

0.99–1.05

1.03

0.01

1.01–1.05

1.02

0.09

1.00–1.03

BMI (Kg/m2)

1.00

0.83

0.96–1.04

0.97

0.39

0.92–1.04

0.95

0.04

0.91–0.998

0.97

0.54

0.95–1.03

Statin use

2.94

0.02

1.93–4.47

2.53

0.02

1.18–5.44

2.59

<  0.01

1.47–4.55

1.22

0.41

0.76–1.97

Serum albumin (g/L)

1.00

0.82

0.97–1.04

1.01

0.63

0.96–1.08

1.02

0.43

0.97–1.07

0.96

0.01

0.92–0.99

Male

1.72

0.02

1.10–2.67

0.64

0.24

0.30–1.36

0.84

0.54

0.47–1.48

0.69

0.14

0.42–1.14

  1. MetS Metabolic syndrome; LDL: LDL cholesterol; BMI Body mass index; CHD Coronary heart disease. PAD 3–4 Stage III or IV peripheral arterial disease; CHF Congestive heart failure